441P - Malignant diseases diagnosed in people living with HIV in Japan

Background

The introduction of antiretroviral therapy has decreased the incidence rate of acquired immunodeficiency syndrome (AIDS)-defining malignancies (ADM) among people living with human immunodeficiency virus (HIV; PLWH); however, the incidence and mortality rates of non-AIDS-defining malignancies (NADM) have remained high in PLWH compared to non-HIV-infected patients. Most studies on this topic were based on the population of Western countries with limited data on the Asian population. This is of significant concern given the different epidemiological background of PLWH in each area. To the best of our knowledge, there are no previous reports which include the entire spectrum of malignant diseases among PLWH in Japan. Herein, we report a retrospective study of malignant diseases among PLWH in one of the designated centers for HIV infection in Japan.

Methods

We retrospectively reviewed patients with HIV infection who were diagnosed with malignant diseases at our institution between 2011 and 2021. The clinical profile and pathological characteristics were retrieved from medical records.

Results

A total of 237 patients were diagnosed with malignant diseases. Among them, 225 were male. ADM and NADM were diagnosed in 102 (43.1%) and 135 (56.9%) patients, respectively. Among the patients diagnosed with ADM, 55 (53.9%) had non-Hodgkin lymphoma, 44 (43.1%) had Kaposi sarcoma, and 3 (3%) had invasive cervical cancer. The most common neoplasm among the NADM was colorectal cancer (19, 14.1%), followed by anal cancer (15, 11.1%), hepatocellular carcinoma (14, 10.4%), gastric cancer (9.6%), head and neck squamous cell carcinoma (11, 8.1%), and lung cancer (10, 7.4%). The proportion of patients with ADM decreased from 2011 to 2021. Approximately 70% of malignant diseases diagnosed between 2020 and 2021 were NADM.

Conclusions

Most of our patients were male, and the proportion of patients with NADM increased from 2011 to 2021. The most neoplasm among the NADM was colorectal cancer. Further analysis is necessary to reveal the effect of HIV infection on the treatment of malignant diseases.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

A grant from the Japan Agency for Medical Research and Development (AMED) Grant No. 22fk0410038h0002.

Disclosure

A. Shimomura: Financial Interests, Personal, Invited Speaker: Chugai pharmaceutical, Eli-Lilly Japan, AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca, Daiichi-sankyo, Taiho pharmaceutical, Eisai. C. Shimizu: Financial Interests, Institutional, Research Grant: Eli-Lilly. All other authors have declared no conflicts of interest.